Advertisement

Ads Placeholder
Loading...

InflaRx N.V.

IF0.DEXETRA
Healthcare
Biotechnology
2.94
0.00(0.00%)
German Market is Open • 15:00

InflaRx N.V. (IF0.DE) Stock Competitors & Peer Comparison

See (IF0.DE) competitors and their performances in Stock Market.

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
IF0.DE€2.94+0.00%129.9M-2.43-€1.21N/A
NOV.DE€31.58-0.74%139.5B10.19€3.08+4.06%
VX1.DE€385.95-0.10%98.9B29.31€13.28N/A
DUL.DE€279.05-2.58%37.8B140.97€2.02N/A
22UA.F€77.30+1.84%19.4B-16.39-€4.70N/A
0QF.F€43.41+3.86%17.1B-6.84-€6.32N/A
BM8.DE€61.96-1.71%11.8B88.51€0.70N/A
EX9.DE€32.28+1.22%9.2B35.47€0.91N/A
BBZA.DE€48.80+0.62%2.7B-5.60-€8.60+5.09%
MOR.DE€67.25-0.66%2.5B-12.16-€5.53N/A
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

IF0.DE vs NOV.DE Comparison April 2026

IF0.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IF0.DE stands at 129.9M. In comparison, NOV.DE has a market cap of 139.5B. Regarding current trading prices, IF0.DE is priced at €2.94, while NOV.DE trades at €31.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IF0.DE currently has a P/E ratio of -2.43, whereas NOV.DE's P/E ratio is 10.19. In terms of profitability, IF0.DE's ROE is -0.45%, compared to NOV.DE's ROE of +0.61%. Regarding short-term risk, IF0.DE is less volatile compared to NOV.DE. This indicates potentially lower risk in terms of short-term price fluctuations for IF0.DE.Check NOV.DE's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions